Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVT-001
- Development stage
- Preclinical
- Lead developer
- Centenara Labs
- Modality
- Small Molecules
01
Overview
CVT-001 is a vascular-targeted small molecule therapy being developed by Centenara Labs (formerly Rejuveron Life Sciences AG) within its Vascular Program. The drug is designed to target and repair the brain vasculature to treat various neurodegenerative disorders. By focusing on slowing down or reversing damage to the blood-brain barrier and cerebral blood vessels, CVT-001 aims to address the underlying vascular contributions to age-related neurodegeneration. The program utilizes artificial intelligence and medicinal chemistry to identify and design molecules for specific targets identified through aging research. As of early 2024, the asset is in the discovery stage of development.
Beyond the preview
Go deeper on CVT-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVT-001.